Table 4 Logistic regression model of potential risk factors for lower patient satisfaction
Factor | Q-score ≥ 74 | Q-score < 74 | OR (95% CI)a | OR (95% CI)b |
|---|---|---|---|---|
BMI (kg/m2) | ||||
< 25 | 31 (54.4%) | 26 (45.6%) | 1 | 1 |
≥ 25 to < 30 | 21 (47.7%) | 23 (52.3%) | 1.31 (0.59–2.87) | 1.28 (0.58–2.84) |
≥ 30 | 9 (50.0%) | 9 (50.0%) | 1.19 (0.41–3.44) | 1.18 (0.40–3.46) |
Age (years) | ||||
< 50 | 18 (56.3%) | 14 (43.8%) | 1 | 1 |
50–65 | 21 (46.7.7%) | 24 (53.3%) | 1.47 (0.59–3.66) | 1.44 (0.58–3.60) |
> 65 | 22 (52.4%) | 20 (47.6%) | 1.17 (0.46–2.95) | 1.14 (0.45–2.91) |
BI-RADS® classification of breast density | ||||
High density(C–D) | 27 (64.3%) | 15 (35.7%) | 1 | 1 |
Low density (A–B) | 34 (44.2%) | 43 (55.8%) | 2.28 (1.05–4.94) | 2.32 (1.02–5.29) |
Smoker | ||||
No | 53 (52.5%) | 48 (47.5%) | 1 | 1 |
Yes | 4 (28.6%) | 10 (71.4%) | 2.76 (0.81–9.38) | 2.59 (0.74–9.12) |
EPBVE (%)c | ||||
< 15 | 31 (50.8%) | 30 (49.2%) | 1 | 1 |
≥ 15 | 25 (51.0%) | 24 (49.0%) | 0.99 (0.47–2.11) | 1.00 (0.45–2.21) |
Specimen weight (grams) | ||||
< 100 | 40 (58.8%) | 28 (41.2%) | 1 | 1 |
≥ 100 | 17 (38.6%) | 27 (61.4%) | 2.27 (1.05–4.93) | 2.23 (0.99–5.06) |
Axillary clearance | ||||
No | 48 (57.8%) | 35 (42.2%) | 1 | 1 |
Yes | 13 (36.1%) | 23 (63.9%) | 2.43 (1.08–5.44) | 2.46 (1.09–5.56) |
Neoadjuvant chemotherapy | ||||
No | 55 (56.1%) | 43 (43.9%) | 1 | 1 |
Yes | 6 (28.6%) | 15 (71.4%) | 3.20 (1.15–8.93) | 3.26 (1.15–9.24) |
Adjuvant chemotherapy | ||||
No | 47 (54.0%) | 40 (46.0%) | 1 | 1 |
Yes | 14 (43.8%) | 18 (56.3%) | 1.51 (0.67–3.42) | 1.54 (0.67–3.52) |
Adjuvant endocrine therapy | ||||
No | 15 (48.4%) | 16 (51.6%) | 1 | 1 |
Yes | 46 (52.3%) | 42 (47.7%) | 0.86 (0.38–1.94) | 0.82 (0.35–1.89) |